-$0.23 Earnings Per Share Expected for Marinus Pharmaceuticals Inc (MRNS) This Quarter

Analysts predict that Marinus Pharmaceuticals Inc (NASDAQ:MRNS) will post earnings of ($0.23) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Marinus Pharmaceuticals’ earnings. The highest EPS estimate is ($0.20) and the lowest is ($0.26). Marinus Pharmaceuticals reported earnings per share of ($0.24) during the same quarter last year, which suggests a positive year over year growth rate of 4.2%. The company is expected to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Marinus Pharmaceuticals will report full-year earnings of ($0.90) per share for the current year, with EPS estimates ranging from ($1.26) to ($0.55). For the next financial year, analysts expect that the company will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.25) to ($0.49). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Marinus Pharmaceuticals.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03).

Several analysts have weighed in on MRNS shares. Leerink Swann started coverage on Marinus Pharmaceuticals in a report on Wednesday, February 6th. They set an “outperform” rating and a $10.00 price objective for the company. Svb Leerink reissued an “outperform” rating on shares of Marinus Pharmaceuticals in a report on Wednesday, February 6th. Zacks Investment Research cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. Mizuho cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $13.00 to $5.00 in a report on Wednesday, February 27th. Finally, Jefferies Financial Group started coverage on Marinus Pharmaceuticals in a report on Tuesday, March 5th. They set a “buy” rating and a $10.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Marinus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $14.94.

NASDAQ MRNS traded up $0.01 on Friday, hitting $4.61. 185,125 shares of the company were exchanged, compared to its average volume of 628,966. The company has a market cap of $241.75 million, a price-to-earnings ratio of -5.12 and a beta of 3.25. Marinus Pharmaceuticals has a 1-year low of $2.36 and a 1-year high of $10.54.

Several hedge funds have recently made changes to their positions in MRNS. Meeder Asset Management Inc. increased its stake in shares of Marinus Pharmaceuticals by 1,082.4% in the 4th quarter. Meeder Asset Management Inc. now owns 10,819 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 9,904 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Marinus Pharmaceuticals by 1,465.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,047 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 9,405 shares during the last quarter. Gabelli Funds LLC bought a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $49,000. IPG Investment Advisors LLC bought a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $50,000. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of Marinus Pharmaceuticals in the 1st quarter valued at about $56,000. 65.63% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Article: Systematic Risk and Investors

Get a free copy of the Zacks research report on Marinus Pharmaceuticals (MRNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.